Biotech. Stocks Alert: Affymax, Dendreon Corporation, Exelixis, Celgene Corporation

Lakeway, TX -- (SBWIRE) -- 02/26/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Affymax, Inc.(NASDAQ:AFFY) moved down 85.35% and closed at $2.42. Affymax, Inc. is a biopharmaceutical company engaged in developing drugs to improve the treatment of serious and often life-threatening conditions. Its product candidate, peginesatide, is for the treatment of anemia in chronic kidney disease patients on dialysis.

How Should Investors Trade AFFY After The Recent Movement? Find Out Here

Dendreon Corporation(NASDAQ:DNDN) lost 4.41% and closed at $5.42. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. Dendreon’s product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE (sipuleucel-T), is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer.

Is DNDN Strong Buy After The Recent Strong Gains? Get Free Trend Analysis Here

Exelixis, Inc.(NASDAQ:EXEL) increased 1.59% and closed at $4.48. Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds.

Is EXEL a Buying Opportunity After The Recent Plunge? Don’t Miss Out Our Latest Report Here

Celgene Corporation(NASDAQ:CELG) fell 2.61% and closed at $99.00. Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

How Should Investors Trade CELG After The Latest Earnings Report? Find Out Here

About bestdamnpennystocks.com
Best Damn Penny Stocks’ team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by Bestdamnpennystocks.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Bestdamnpennystocks.com does expect that investors will buy and sell securities based on information assembled and presented in Bestdamnpennystocks.com. PLEASE always do your own due diligence, and consult your financial advisor.